Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:CMND NASDAQ:PRPH NASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACMNDClearmind Medicine$3.98+36.8%$6.81$2.10▼$524.00$4.06M0.642.75 million shs41.77 million shsPRPHProPhase Labs$0.11-12.0%$0.11$0.07▼$6.66$662K0.09257,746 shs68,472 shsSHPHShuttle Pharmaceuticals$0.45-7.8%$0.74$0.38▼$6.19$2.66M0.181.37 million shs2.48 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%CMNDClearmind Medicine0.00%+11.17%-29.24%-65.09%-98.90%PRPHProPhase Labs0.00%+10.11%-8.33%-20.06%-97.14%SHPHShuttle Pharmaceuticals0.00%-13.52%-35.68%-50.49%-90.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACMNDClearmind Medicine$3.98+36.8%$6.81$2.10▼$524.00$4.06M0.642.75 million shs41.77 million shsPRPHProPhase Labs$0.11-12.0%$0.11$0.07▼$6.66$662K0.09257,746 shs68,472 shsSHPHShuttle Pharmaceuticals$0.45-7.8%$0.74$0.38▼$6.19$2.66M0.181.37 million shs2.48 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%CMNDClearmind Medicine0.00%+11.17%-29.24%-65.09%-98.90%PRPHProPhase Labs0.00%+10.11%-8.33%-20.06%-97.14%SHPHShuttle Pharmaceuticals0.00%-13.52%-35.68%-50.49%-90.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/ACMNDClearmind Medicine 0.00N/AN/AN/APRPHProPhase Labs 1.00SellN/AN/ASHPHShuttle Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PRPH, SHPH, CMND, and ARAV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/18/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/4/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAraviveN/AN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/A$14.41 per shareN/APRPHProPhase Labs$5.06M0.13N/AN/A$2.46 per share0.04SHPHShuttle PharmaceuticalsN/AN/AN/AN/A$1.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAraviveN/A-$0.90N/AN/AN/AN/AN/AN/AN/ACMNDClearmind Medicine-$3.86M-$197.20N/AN/AN/AN/A-207.53%-100.70%N/APRPHProPhase Labs-$53.36M-$3.90N/AN/AN/A-825.01%-482.05%-88.90%6/8/2026 (Estimated)SHPHShuttle Pharmaceuticals-$11.72M-$4.77N/AN/AN/AN/A-408.34%-138.15%N/ALatest PRPH, SHPH, CMND, and ARAV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SHPHShuttle PharmaceuticalsN/A-$0.43N/A-$0.43N/AN/A3/31/2026Q4 2025SHPHShuttle PharmaceuticalsN/A$0.06N/A$0.06N/AN/A3/12/2026Q1 2026CMNDClearmind MedicineN/A-$33.20N/A-$3.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/A-100.00%N/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/ACMNDClearmind MedicineN/A3.793.79PRPHProPhase Labs0.140.140.14SHPHShuttle PharmaceuticalsN/A0.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%CMNDClearmind Medicine96.05%PRPHProPhase Labs9.45%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipARAVAravive60.40%CMNDClearmind MedicineN/APRPHProPhase Labs9.60%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive20N/AN/ANo DataCMNDClearmind MedicineN/A1.02 millionN/ANot OptionablePRPHProPhase Labs1306.02 million5.44 millionOptionableSHPHShuttle Pharmaceuticals55.85 million5.11 millionNot OptionablePRPH, SHPH, CMND, and ARAV HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals (NASDAQ:SHPH) Shares Up 0.6% - Still a Buy?May 27, 2026 | americanbankingnews.comShuttle Pharmaceuticals Holdings Inc SHPHMay 19, 2026 | morningstar.comMShuttle Pharmaceuticals Holdings, Inc.May 15, 2026 | edition.cnn.comShuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining RigsMay 14, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Completes Merger and PIPE FinancingMay 7, 2026 | tipranks.comE.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin MinerMay 7, 2026 | globenewswire.comShuttle to Acquire United Dogecoin in Push to Build Public DOGE Mining PlatformMay 2, 2026 | finance.yahoo.comWhy is SHPH stock soaring today? Dogecoin mining pivot sparks rallyMay 2, 2026 | msn.comShuttle Pharmaceuticals Transforms into Dogecoin Mining PowerhouseMay 1, 2026 | tipranks.comUnited Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining OperationMay 1, 2026 | newsfilecorp.comNShuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin MinerApril 30, 2026 | newsfilecorp.comNRETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 27, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 26, 2026 | newsfilecorp.comNE.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals’ $3.5 Million Public OfferingMarch 12, 2026 | markets.businessinsider.comE.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public OfferingMarch 12, 2026 | globenewswire.comShuttle Pharmaceuticals Announces $3.5 Million Public OfferingMarch 6, 2026 | newsfilecorp.comNShuttle Pharma Extends Consulting Agreement With Interim Co-CEOFebruary 2, 2026 | tipranks.comUtah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs – and Why Molecule.ai's Drug Discovery Platform Matters More Than EverJanuary 13, 2026 | cantechletter.comCUtah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than EverJanuary 13, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Accelerates Equity Payment in Asset DealDecember 29, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRPH, SHPH, CMND, and ARAV Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 06/5/2026Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Clearmind Medicine NASDAQ:CMND$3.98 +1.07 (+36.77%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.72 -0.26 (-6.58%) As of 06/5/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.ProPhase Labs NASDAQ:PRPH$0.11 -0.02 (-12.00%) As of 06/5/2026 02:48 PM EasternProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Shuttle Pharmaceuticals NASDAQ:SHPH$0.45 -0.04 (-7.82%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.43 -0.03 (-5.95%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
